ICAM1 and Alzheimer disease: In the present study, using a large cohort of well-characterized patients, we show increased levels of ICAM-1, VCAM-1, IL-15, and Flt-1in AD at the preclinical, prodromal, and dementia stage, indicating that neuroinflammatory pathways are activated early in the disease course.